There is no publicly reported securities class action or shareholder lawsuit against Inspire Veterinary Partners, Inc. on the record reviewed here. What searches for an “Inspire Veterinary Partners lawsuit” tend to surface is a different story: a cascade of Nasdaq listing violations, heavily dilutive financings, a private release tied to one of the company’s acquisitions, and a January 2026 delisting followed by voluntary SEC deregistration in May 2026 that effectively ended the company’s life as a public reporting entity.
The distinction matters. Shareholders who lost money on IVPR stock did so through market and regulatory events, not through a courtroom judgment, and the company’s remaining disclosures are limited because it is no longer obligated to file with the SEC.
The Kauai Veterinary Clinic Release
The closest item in Inspire’s public filings to a lawsuit is a general release agreement dated March 6, 2024, tied to the company’s acquisition of Kauai Veterinary Clinic in Hawaii. Four individuals connected to the clinic — Kenneth Seth Lundquist, DVM; Charles “Chuck” Keiser, DVM; Don I. Williamson, Jr., DVM; and the Estate of Gregory Armstrong — each received $5,000 in restricted stock, 61,501 shares apiece, in exchange for releasing Inspire from “all potential, pending, or alleged claims, issues or complaints” arising from the acquisition.
The filings do not describe what the underlying grievances were, and they do not indicate that any formal lawsuit was filed before the release was signed. On the same date, Charles Keiser signed a separate consulting agreement worth roughly $151,700 in stock (1,865,875 shares) that also released any claims he had against the company.
Nasdaq Violations and the 2026 Delisting
Inspire went public on the Nasdaq Capital Market in August 2023 and received its first deficiency notice that November for failing to maintain a $1.00 minimum bid price. In March 2024, Nasdaq issued a staff determination to delist the stock after the closing bid price sat at $0.10 or less for ten consecutive trading days.
To hold onto its listing, Inspire executed two reverse stock splits: 1-for-100 in May 2024 and 1-for-25 in January 2025. The cumulative 250-to-1 ratio later made the company ineligible for a standard compliance cure period.
A separate violation surfaced in September 2024. Nasdaq found that a July 2024 offering of 6 million units at $1.00 per unit, placed through Spartan Capital Securities, did not qualify as a “public offering” under its shareholder-approval rules. Because the transaction issued 20% or more of the pre-transaction shares below the minimum price without prior shareholder approval, it violated Listing Rule 5635(d). Inspire obtained after-the-fact shareholder ratification. Nasdaq resolved the matter with a Public Reprimand Letter and placed the company under a one-year Mandatory Panel Monitor through December 2025.
The end came in November 2025, when Nasdaq notified Inspire that its stock had again fallen below the minimum bid price for 30 consecutive business days. The company appealed. A hearing was held on January 13, 2026, and one week later, on January 20, 2026, the Nasdaq Hearings Panel denied continued listing. Trading was suspended the next morning.
Dilution That Erased Shareholder Value
While no investor suit has been reported, the mechanics that hurt shareholders are documented in the filings. Shares outstanding rose 64% as of August 2025, and in January 2026 the company authorized up to 700 million Class A common shares.
Two debt-for-equity swaps with Target Capital 1 LLC, managed by Dmitriy Shapiro, illustrate the terms Inspire was accepting near the end. In December 2025, it cancelled $150,000 of debt from a June 2025 promissory note in exchange for 3 million shares at $0.05 each. Weeks later, in January 2026, it cancelled another $250,000 of the same note for 25 million shares at $0.01 each, a penny apiece and a steep discount to the roughly $0.04 trading price at the time.
Also in December 2025, Inspire issued 9.45 million shares to 622 Capital LLC under a consulting agreement for “business development services related to business financing opportunities.” An S-1 filed around the same time proposed registering up to 200 million more shares for resale by a selling stockholder connected to convertible notes, a move that would have taken the share count from roughly 119 million to 319 million.
Earlier rounds followed the same pattern: a November 2023 stock purchase agreement letting Tumim Stone Capital LLC buy up to $30 million in shares; $500,000 in senior convertible notes in March 2024 with a $0.03 conversion price and default step-downs; and a March 2025 registered direct offering placed by D. Boral Capital that raised about $2 million at $1.83 per share with two series of warrants attached.
Financial Condition and Governance
Inspire reported a $14.3 million net loss for fiscal year 2024, an accumulated deficit of $36.4 million, and just $723,690 in cash and restricted cash as of December 31, 2024. Auditors flagged “substantial doubt” about the company’s ability to continue as a going concern for both 2023 and 2024. Its own filings said the company had a “limited operating history,” was “not profitable,” and “may never become profitable,” and that management lacked experience running a public company.
Governance was concentrated. Non-independent directors, officers, and their affiliates controlled roughly 98% of the voting power, making Inspire effectively a controlled company. It never filed a management assessment of internal controls under Section 404(b) of the Sarbanes-Oxley Act, and its filings warned that weak internal controls could materially harm the business. CEO Kimball Carr, who is also President and Chairman, personally guaranteed the company’s master lending and credit facility.
Where the Stock Stands Now
After the January 2026 delisting, IVPR shares moved to the OTCQB Venture Market and traded at $0.01 on the first day. Inspire then missed the SEC’s March 2026 deadline for its annual 10-K.
On May 8, 2026, the company filed a Form 15 to voluntarily deregister its Class A Common Stock, ending its obligation to file periodic reports. The filing reported only 113 holders of record. By mid-June 2026, the stock had been downgraded to the Pink Limited Market, the lowest OTC tier, and was trading at about $0.001 per share, a market capitalization of roughly $269,000.
For anyone still holding IVPR shares or looking for recourse, the practical reality is that the company no longer files with the SEC, no securities class action against it has been reported in the record, and the last documented settlement-type payments were the modest stock releases given to the Kauai clinic sellers in 2024. Anyone believing they have a claim would need to consult a securities attorney directly, because the public paper trail on Inspire has largely stopped.